24.6-month median overall survival observed in relapsed/refractory multiple myeloma patients treated with Pfizer's ELREXFIOtm in Phase 2 MagnetisMM-3 study.
ELREXFIOtm (elranatamab-bcmm) from Pfizer Inc. shows a median overall survival of 24.6 months in patients with relapsed or refractory multiple myeloma, according to the Phase 2 MagnetisMM-3 study. The data will be presented at the European Hematology Association (EHA) Hybrid Congress in Madrid, Spain. These results support the clinical benefit previously demonstrated by ELREXFIOtm.
June 14, 2024
3 Articles